Genetic Signatures (GSS) H1 2025 earnings summary

Executive summary

• Sales increased 136% year-over-year in H1 FY25 to $8.5 million, driven by strong respiratory demand in Australia and US market entry.

• Gross margin improved to 59% from 42% year-over-year.

• Statutory loss widened to $15.2 million, including a $6.8 million impairment from ceasing next-gen instrument development.

• First US commercial contract secured and FDA clearance obtained for the EasyScreen Gastrointestinal Parasite Detection Kit.

• Cash reserves were $40.8 million as of 31 December 2024, with no debt.

Financial highlights

• Revenue for H1 FY25 was $8.5 million, up from $3.6 million in the prior period, with international sales at 9.4%.

• Gross profit margin increased to 59% (1H FY24: 42%).

• Underlying loss improved by 20% to $8.4 million, but statutory loss widened to $15.2 million due to impairment.

• Operating cash outflows were $8–8.4 million for the half; $5 million received from R&D tax incentive and $8–8.2 million raised from equity.

• Cash and equivalents at 31 December 2024 were $40.8 million.

Outlook and guidance

• Expectation for continued growth in international revenue, especially in the US and Europe.

• Multiple US customer sites nearing contract finalization, with a strong pipeline of over 65 prospects.

• Focus on automation, product performance, and adapting commercial instruments for high-throughput solutions.

• Respiratory testing demand in Australia remains strong and is expected to persist.

• Confident in commencement of regular US sales for the EasyScreen Gastrointestinal Parasite Detection Kit once procurement is complete.